Published in Blood Weekly, February 19th, 2004
"Several trials have shown the superior impact of high-dose melphalan (usually 200 mg/m2, MEL200) vs. standard therapy in myeloma patients. Intermediate-dose melphalan (100 mg/m2, MEL100) is also superior to the standard dose, but has not been clinically compared with MEL200. A total of 90 patients at diagnosis were treated with two MEL100 courses," researchers in Italy report.
"Their clinical outcome was compared with that of a control group of 90 pair mates matched for serum...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.